Tumor Biology

, Volume 36, Issue 3, pp 1445–1453 | Cite as

RKIP promotes cisplatin-induced gastric cancer cell death through NF-κB/Snail pathway

  • Hongyi Liu
  • Peng Li
  • Bing Li
  • Peng Sun
  • Jiajin Zhang
  • Baishi Wang
  • Baoqing Jia
Research Article


The objectives of this study were to explore the expression profiles of Raf kinase inhibitor protein (RKIP) in human gastric cancer cell line (SGC-7901) and cisplatin-resistant cell line (SGC-7901/DDP) and investigate the role of RKIP in the sensitivity of human gastric cancer cells to cisplatin and its signaling pathways, with an attempt to identify new approaches and strategies for the management of gastric cancer. The human gastric cancer cell line (SGC-7901) and cisplatin-resistant cell line (SGC-7901/DDP) were separately cultured in vitro. The expression profiles of RKIP in these two cell lines were detected by Western blotting. Forty-eight hours after the transfection of RKIP siRNA in SGC-7901 cells, the change of RKIP expression in the cells was detected using Western blotting, and the change of cell viability after the interference of RKIP expression was determined using 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) method. The effect of the ectopic expression of RKIP on the cisplatin-induced viability of gastric cancer cell was detected using MTT method. The effect of the ectopic expression of RKIP on the cisplatin-induced apoptosis of gastric cancer cell was detected using flow cytometry after having been double stained with Annexin V/PI. The effect of the ectopic expression of RKIP on the NF-κB and Snail expressions in cisplatin-induced gastric cancer cells was detected using Western blotting. As shown by the Western blotting, the expression of RKIP in SGC-7901/DDP cells significantly decreased when compared with that in SGC-7901 cells (P < 0.05). Compared with the control group, the expression of RKIP in SGC-7901 cells significantly decreased 48 h after the transfection of RKIP siRNA (P < 0.01). After the SGC-7901 cells were transfected with RKIP siRNA, the cell viability was significantly increased (P < 0.05); after the SGC-7901/DDP cells were transfected with RKIP recombinant plasmid, the cell viability was significantly decreased (P < 0.05). After the RKIP expression was suppressed in the cisplatin-treated SGC-7901 cells, the cell viability significantly increased (P < 0.05), and the amount of apoptotic cells significantly decreased (P < 0.05). In contrast, after the RKIP overexpression in the cisplatin-treated SGC-7901/DDP cells, the cell viability significantly decreased (P < 0.05), and the amount of apoptotic cells significantly increased (P < 0.05). The suppression of RKIP expression in SGC-7901 cells could significantly promote the increase of NF-κB expression (P < 0.05); in contrast, the increased expression of RKIP in SGC-7901/DDP cells significantly inhibited the expression of Snail (P < 0.05). The expression of RKIP is downregulated in cisplatin-resistant cell line (SGC-7901/DDP). The overexpression of RKIP can enhance the sensitivity of human gastric cancer cells to cisplatin, which may be achieved via the NF-κB/Snail signaling pathway.


RKIP Gastric cancer Cisplatin Apoptosis NF-κB/Snail 


Conflicts of interest



  1. 1.
    Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10–21.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251–61.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Ryu KW, SENORITA Study Group. Future perspective of laparoscopic surgery for gastric cancer: sentinel node navigation function-preserving surgery for early gastric cancer. Transl Gastrointest Cancer. 2013;2:160–3.Google Scholar
  4. 4.
    Ling TC, Kang JI, Slater JD, Yang GY. Proton therapy for gastrointestinal cancers. Transl Cancer Res. 2012;1:150–8.Google Scholar
  5. 5.
    Wang YX, Wang DW, Zhu XM, Zhao F, Leung KC. Carbon coated superparamagnetic iron oxide nanoparticles for sentinel lymph nodes mapping. Quant Imaging Med Surg. 2012;2:53–6.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Al Mushref M, Srinivasan S. Effect of high fat-diet and obesity on gastrointestinal motility. Ann Transl Med. 2013;1:14.PubMedCentralGoogle Scholar
  7. 7.
    Yamada Y. Molecular therapy for gastric cancer. Chin Clin Oncol. 2013;2:5.PubMedGoogle Scholar
  8. 8.
    Kang B, Sun XH. Regulation of cancer stem cells by RING finger ubiquitin ligases. Stem Cell Investig. 2014;1:5.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 1999;401:173–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Zeng L, Imamoto A, Rosner MR. Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin Ther Targets. 2008;12:1275–87.CrossRefPubMedGoogle Scholar
  11. 11.
    Granovsky AE, Rosner MR. Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res. 2008;18:452–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Khamis ZI, Iczkowski KA, Sang QX. Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents. Med Res Rev. 2012;32:1026–77.CrossRefPubMedGoogle Scholar
  13. 13.
    Morecroft I, Doyle B, Nilsen M, Kolch W, Mair K, Maclean MR. Mice lacking the Raf-1 kinase inhibitor protein exhibit exaggerated hypoxia-induced pulmonary hypertension. Br J Pharmacol. 2011;163:948–63.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Beshir AB, Ren G, Magpusao AN, Barone LM, Yeung KC, Fenteany G. Raf kinase inhibitor protein suppresses nuclear factor-kappaB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. Cancer Lett. 2010;299:137–49.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Martinho O, Pinto F, Granja S, Miranda-Goncalves V, Moreira MA, Ribeiro LF, et al. RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy. PLoS ONE. 2013;8:e59104.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014;33:117–23.CrossRefGoogle Scholar
  17. 17.
    Marcu LG. Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments. BioMed Res Int. 2013;2013:817279.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ciarimboli G. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res. 2014;34:547–50.PubMedGoogle Scholar
  19. 19.
    Peres LA, Cunha Junior AD. Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol Orgao Oficial Soc Bras Latino-Am Nefrol. 2013;35:332–40.Google Scholar
  20. 20.
    Smith HS, Smith JM, Seidner P. Opioidinduced nausea and vomiting. Ann Palliat Med. 2012;1:121–9.PubMedGoogle Scholar
  21. 21.
    Peters GJ, Avan A, Ruiz MG, Orsini V, Avan A, Giovannetti E, et al. Predictive role of repair enzymes in the efficacy of cisplatin combinations in pancreatic and lung cancer. Anticancer Res. 2014;34:435–42.PubMedGoogle Scholar
  22. 22.
    Lombardi G, Pambuku A, Bellu L, Della Puppa A, Rumano L, Gardiman MP, et al. Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. Chemotherapy. 2013;59:176–80.CrossRefPubMedGoogle Scholar
  23. 23.
    Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, et al. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst. 2003;95:878–89.CrossRefPubMedGoogle Scholar
  24. 24.
    Xu YF, Yi Y, Qiu SJ, Gao Q, Li YW, Dai CX, et al. PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. J Hepatol. 2010;53:872–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-kappaB/Snail/RKIP/PTEN circuit. Genes Cancer. 2010;1:409–20.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Al-Mulla F, Hagan S, Al-Ali W, Jacob SP, Behbehani AI, Bitar MS, et al. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J Clin Pathol. 2008;61:524–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Li HZ, Gao Y, Zhao XL, Liu YX, Sun BC, Yang J, et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res. 2009;7:832–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Minn AJ, Bevilacqua E, Yun J, Rosner MR. Identification of novel metastasis suppressor signaling pathways for breast cancer. Cell Cycle. 2012;11:2452–7.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Bonavida B, Baritaki S. The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-kappaB/Snail/YY1/RKIP/PTEN Circuitry. Crit Rev Oncog. 2011;16:211–26.CrossRefPubMedGoogle Scholar
  30. 30.
    Li SW, Wang H, Liu ML, Zhang HB, Xiang YQ, Lv X, et al. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study. Med Oncol. 2013;30:322.CrossRefPubMedGoogle Scholar
  31. 31.
    Jagadeesh D, Smith MR. Novel targeted therapies in peripheral T cell lymphoma. Discov Med. 2013;15:367–78.PubMedGoogle Scholar
  32. 32.
    Morotti M, Becker C, Menada MV, Ferrero S. Targeting tyrosine-kinase in ovarian cancer. Expert Opin Investig Drugs. 2013;22:1265–79.CrossRefPubMedGoogle Scholar
  33. 33.
    Lubin J, Markowska A, Knapp P. Factors affecting response of chemotherapy in women with ovarian cancer. Eur J Gynaecol Oncol. 2012;33:644–7.PubMedGoogle Scholar
  34. 34.
    Breier A, Gibalova L, Seres M, Barancik M, Sulova Z. New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem. 2013;13:159–70.CrossRefPubMedGoogle Scholar
  35. 35.
    Al-Mulla F, Bitar MS, Taqi Z, Yeung KC. RKIP: much more than Raf kinase inhibitory protein. J Cell Physiol. 2013;228:1688–702.CrossRefPubMedGoogle Scholar
  36. 36.
    Escara-Wilke J, Yeung K, Keller ET. Raf kinase inhibitor protein (RKIP) in cancer. Cancer Metastasis Rev. 2012;31:615–20.CrossRefPubMedGoogle Scholar
  37. 37.
    Altura BM, Shah NC, Shah GJ, Zhang A, Li W, Zheng T, et al. Short-term Mg deficiency upregulates protein kinase C isoforms in cardiovascular tissues and cells; relation to NF-kB, cytokines, ceramide salvage sphingolipid pathway and PKC-zeta: hypothesis and review. Int J Clin Exp Med. 2014;7:1–21.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Fuchs O. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets. 2013;13:16–34.CrossRefPubMedGoogle Scholar
  40. 40.
    Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S. Roles each of Snail, Yin Yang 1 and RKIP in the regulation of tumor cells chemo-immuno-resistance to apoptosis. Forum Immunopathol Dis Ther. 2013;4.Google Scholar
  41. 41.
    Rapozzi V, Umezawa K, Xodo LE. Role of NF-kappaB/Snail/RKIP loop in the response of tumor cells to photodynamic therapy. Lasers Surg Med. 2011;43:575–85.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Hongyi Liu
    • 1
  • Peng Li
    • 1
  • Bing Li
    • 1
  • Peng Sun
    • 1
  • Jiajin Zhang
    • 1
  • Baishi Wang
    • 1
  • Baoqing Jia
    • 1
  1. 1.Department of Surgical OncologyGeneral Hospital of Chinese People’s Liberation ArmyBeijingChina

Personalised recommendations